Additionally, it promotes the secretion of chemokines (CXCL1,CXCL2, CXCL8, CCL2, CCL7, CCL20), which recruit neutrophils, macrophages,and lymphocytes to the synovial membrane, contributing to the inflammatoryresponse.66,67 Interestingly, the absence of IL-17 hasbeen shown to ameliorate arthritis development.68 As a result, IL-17A blockers, such as Secukinumab, Ixekizumab,and Brodalumab are being explored as promising options for treatingRA.69 Here, IL17A is linked to arthritic joint disease.